Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caris Life Sciences, Inc.CAI · Entity 3706 | Director | May 29, 2026 | June 02, 2026 |
| EXELIXIS, INC.EXEL · Entity 3386 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caris Life Sciences, Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,729 |
Reported balance
After 2026-05-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 1,600 · Balance 17,729 F1: Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026. F2: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 511,702 |
Reported balance
Holding disclosure · report date 2026-05-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 511,702 F2: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.
F2: Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.
EXELIXIS, INC.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,199 |
Reported balance
After 2026-05-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,367 · Balance 127,199 F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. F2: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.
F2: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MONSANTO CO /NEW/
Report date June 07, 2018 · Filed June 07, 2018
Section 16 reporting ended · disclosed 2018-06-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Payment Plan Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-07 · Disposition to issuer · Disposed 39,860 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration").
F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2018 Filed May 25, 2018 00:29 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 7,937 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-18-000109 · wf-form4_152720813374361.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,335 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 24, 2019, subject to the Reporting Person's continuous service through such date. F3 · balance_after: Includes 13,780 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 27, 2018 Filed May 1, 2018 16:23 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 171 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-18-000061 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,860 F1 · shares: Represents dividend equivalents with respect to shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Deferred common stock and dividend equivalents are credited to a stock unit account in the form of hypothetical shares, which vest in installments on the last day of each plan month during the director's term. Shares of deferred stock that do not vest, because of termination as a director or certain changes in committee roles, are forfeited. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0000939767-18-000030 · wf-form4_152003872483676.xml · derivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 19, 2011. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 15,000 | $26.26 | $393,900.00 |
DisclosureSEC source: 0000939767-18-000030 · wf-form4_152003872483676.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,398 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.05 to $26.63. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 28, 2018 Filed Mar 3, 2018 00:59 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $11.66 | $174,900.00 |
DisclosureSEC source: 0000939767-18-000030 · wf-form4_152003872483676.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,398 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 5,843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 16:56 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-18-000032 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,689 F1 · shares: Represents dividend equivalents with respect to shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Deferred common stock and dividend equivalents are credited to a stock unit account in the form of hypothetical shares, which vest in installments on the last day of each plan month during the director's term. Shares of deferred stock that do not vest, because of termination as a director or certain changes in committee roles, are forfeited. Read SEC document |
| October 27, 2017 Filed Oct 30, 2017 16:40 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 174 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000229 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,514 F1 · shares: Represents dividend equivalents with respect to shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Deferred common stock and dividend equivalents are credited to a stock unit account in the form of hypothetical shares, which vest in installments on the last day of each plan month during the director's term. Shares of deferred stock that do not vest, because of termination as a director or certain changes in committee roles, are forfeited. Read SEC document |
| September 01, 2017 Filed Sep 5, 2017 16:36 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 2,346 | $117.21 | $274,974.66 |
DisclosureSEC source: 0001110783-17-000158 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,340 F1 · shares: Represents shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Shares of deferred stock are credited in the form of hypothetical shares to a stock unit account in installments on the last day of each plan month during the director's term. Shares of deferred stock not credited to the stock unit account because of termination as a director are forfeited. Read SEC document |
| July 28, 2017 Filed Aug 1, 2017 16:40 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 170 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000132 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,994 F1 · shares: Represents dividend equivalents with respect to shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Deferred common stock and dividend equivalents are credited to a stock unit account in the form of hypothetical shares, which vest in installments on the last day of each plan month during the director's term. Shares of deferred stock that do not vest, because of termination as a director or certain changes in committee roles, are forfeited. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 11,686 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000115 · wf-form4_149584630514283.xml · derivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,686 Underlying: Common Stock · 11,686 shares Expires 2024-05-24 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:52 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 5,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000115 · wf-form4_149584630514283.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,398 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the sharessubject to the restricted stock unit award on May 25, 2018, subject to the Reporting Person's continuous service through such date. F3 · balance_after: Includes 5.843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 28, 2017 Filed May 2, 2017 16:22 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 169 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000074 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,824 F1 · shares: Represents dividend equivalents with respect to shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Deferred common stock and dividend equivalents are credited to a stock unit account in the form of hypothetical shares, which vest in installments on the last day of each plan month during the director's term. Shares of deferred stock that do not vest, because of termination as a director or certain changes in committee roles, are forfeited. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · derivative · entry 12 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 15,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2008. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 11,250 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · derivative · entry 11 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires 2019-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 11,250 shares of Exelixis, Inc. common stock, became fully exercisable on May 14, 2009. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · derivative · entry 10 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2022-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 28, 2015. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 1,150 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · derivative · entry 9 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,150 shares Expires 2017-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 10,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2007. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 67,400 | $22.58 | $1,521,892.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · nonDerivative · entry 7 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,555 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.40 to $22.78. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 15,000 | $7.97 | $119,550.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · nonDerivative · entry 6 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 11,250 | $4.16 | $46,800.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · nonDerivative · entry 5 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,955 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 40,000 | $3.13 | $125,200.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · nonDerivative · entry 4 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 1,150 | $10.53 | $12,109.50 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · nonDerivative · entry 3 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 8,850 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · derivative · entry 8 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,150 Underlying: Common Stock · 8,850 shares Expires 2017-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 10,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2007. Read SEC document |
| March 01, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 8,850 | $22.18 | $196,293.00 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · nonDerivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,555 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.15 to $22.24. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| March 01, 2017 Filed Mar 4, 2017 01:17 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 8,850 | $10.53 | $93,190.50 |
DisclosureSEC source: 0000939767-17-000023 · wf-form4_148859021275410.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,405 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2017 Filed Jan 31, 2017 16:24 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0001110783-17-000036 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,655 F1 · shares: Represents dividend equivalents with respect to shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Deferred common stock and dividend equivalents are credited to a stock unit account in the form of hypothetical shares, which vest in installments on the last day of each plan month during the director's term. Shares of deferred stock that do not vest, because of termination as a director or certain changes in committee roles, are forfeited. Read SEC document |
| October 28, 2016 Filed Nov 1, 2016 16:41 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 194 | $100.98 | $19,590.12 |
DisclosureSEC source: 0001110783-16-000570 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,475 F1 · shares: Represents dividend equivalents with respect to shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Deferred common stock and dividend equivalents are credited to a stock unit account in the form of hypothetical shares, which vest in installments on the last day of each plan month during the director's term. Shares of deferred stock that do not vest, because of termination as a director or certain changes in committee roles, are forfeited. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 16:59 UTC | MONSANTO CO /NEW/ MON · Entity 165931 | GrantCommon Stock | 1,286 | $106.91 | $137,486.26 |
DisclosureSEC source: 0001110783-16-000504 · edgar.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,281 F1 · shares: Represents shares of deferred common stock deliverable upon termination as a director under the Monsanto Company Non-Employee Director Equity Incentive Compensation Plan. Shares of deferred stock are credited in the form of hypothetical shares to a stock unit account in installments on the last day of each plan month during the director's term. Shares of deferred stock not credited to the stock unit account because of termination as a director are forfeited. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.